CN103889993B - 修饰的肌酸化合物 - Google Patents

修饰的肌酸化合物 Download PDF

Info

Publication number
CN103889993B
CN103889993B CN201280052878.9A CN201280052878A CN103889993B CN 103889993 B CN103889993 B CN 103889993B CN 201280052878 A CN201280052878 A CN 201280052878A CN 103889993 B CN103889993 B CN 103889993B
Authority
CN
China
Prior art keywords
alkyl
compound
creatine
methyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280052878.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103889993A (zh
Inventor
沙哈里亚尔·M·汗
R·C·加德伍德
A·G·罗梅罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gencia Corp
Original Assignee
Gencia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencia Corp filed Critical Gencia Corp
Publication of CN103889993A publication Critical patent/CN103889993A/zh
Application granted granted Critical
Publication of CN103889993B publication Critical patent/CN103889993B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280052878.9A 2011-09-19 2012-09-18 修饰的肌酸化合物 Expired - Fee Related CN103889993B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536280P 2011-09-19 2011-09-19
US61/536,280 2011-09-19
PCT/US2012/055887 WO2013043580A2 (en) 2011-09-19 2012-09-18 Modified creatine compounds

Publications (2)

Publication Number Publication Date
CN103889993A CN103889993A (zh) 2014-06-25
CN103889993B true CN103889993B (zh) 2017-05-31

Family

ID=46982949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280052878.9A Expired - Fee Related CN103889993B (zh) 2011-09-19 2012-09-18 修饰的肌酸化合物

Country Status (8)

Country Link
US (1) US9434753B2 (cg-RX-API-DMAC7.html)
EP (1) EP2758411A2 (cg-RX-API-DMAC7.html)
JP (2) JP2014527969A (cg-RX-API-DMAC7.html)
CN (1) CN103889993B (cg-RX-API-DMAC7.html)
AU (1) AU2012312654B2 (cg-RX-API-DMAC7.html)
CA (1) CA2849073A1 (cg-RX-API-DMAC7.html)
HK (1) HK1200459A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013043580A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20121098A1 (it) * 2012-12-18 2014-06-19 Univ Degli Studi Genova Procedimento per sintetizzare derivati della creatina
CA2906697A1 (en) 2013-03-15 2014-09-18 Gencia Corporation Compositions and methods for treating conditions that affect epidermis
US20160289175A1 (en) * 2013-11-05 2016-10-06 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
US9617230B2 (en) * 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US11021501B2 (en) 2015-03-30 2021-06-01 Farmington Pharma Development Creatine phosphate analog prodrugs, compositions and methods of use thereof
US10883978B2 (en) * 2017-01-31 2021-01-05 Agilent Technologies, Inc. Method and device for calibration of biological flux
JP6919923B2 (ja) * 2017-08-04 2021-08-18 国立大学法人金沢大学 微小空間の加温方法及び発熱体
CN111417620B (zh) 2017-12-01 2023-08-25 奥特吉尼克斯制药公司 肌酸前药、其组合物以及使用方法
KR101920902B1 (ko) * 2017-12-27 2018-11-21 전남대학교 산학협력단 심혈관 질환 조기진단 pet 조영용 화합물 및 그의 용도
US20220153783A1 (en) * 2019-10-30 2022-05-19 Fusion Biotechnology Co., Ltd. Mitochondria-targeting compound and composition comprising same for treating or preventing aging-related diseases
CN115417898B (zh) * 2022-08-02 2024-03-26 浙江工业大学 一种三苯基鏻单体化合物及其制备方法与在制备核酸递送纳米载体中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1454902A (zh) * 2002-04-30 2003-11-12 国际试药株式会社 线粒体肌酸激酶抗体
CN1636572A (zh) * 1998-08-31 2005-07-13 普罗神经细胞有限公司 治疗线粒体性疾病的组合物和方法
CN101848918A (zh) * 2007-09-07 2010-09-29 吉奇亚公司 线粒体组合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH671155A5 (cg-RX-API-DMAC7.html) 1986-08-18 1989-08-15 Clinical Technologies Ass
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2268696T3 (es) * 1994-11-08 2007-03-16 Avicena Group, Inc. Uso de creatina o analogos de creatina para el tratamiento de la enfermedad de huntigton, enfermedad de parkinson y esclerosis lateral amiotrofica.
US20060128671A1 (en) 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
AU759467B2 (en) 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
DE69913712T2 (de) 1998-08-25 2004-10-07 Uab Res Foundation Birmingham Inhibitoren der bakteriellen nad synthetase
ES2223464T3 (es) 1999-02-01 2005-03-01 Eisai Co., Ltd. Compuestos adyuvantes inmunologicos.
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US6355616B1 (en) * 1999-06-25 2002-03-12 Xoma (Us) Technology Ltd. Derivative compounds derived from or based on bactericidal/permeability-increasing protein
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MXPA03002649A (es) 2000-09-27 2003-09-25 Ajinomoto Kk Derivado de benzodiazepina.
JP2005298343A (ja) 2002-03-27 2005-10-27 Ajinomoto Co Inc ベンゾジアゼピン誘導体
PT1599216E (pt) * 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
BRPI0413742B8 (pt) 2003-08-22 2021-05-25 Antipodean Pharmaceuticals Inc composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
JP4648319B2 (ja) * 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US8039587B2 (en) 2003-10-24 2011-10-18 Gencia Corporation Methods and compositions for delivering polynucleotides
CN1997403A (zh) 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
US7915230B2 (en) 2005-05-17 2011-03-29 Molecular Transfer, Inc. Reagents for transfection of eukaryotic cells
US20070066572A1 (en) * 2005-09-14 2007-03-22 Kalyanaraman Balaraman Neuroprotection by positively-charged nitroxides
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2604255B1 (en) 2006-05-05 2017-10-25 Molecular Transfer, Inc. Novel reagents for transfection of eukaryotic cells
ES2391662T3 (es) * 2006-09-28 2012-11-28 Medical Research Council Donadores de óxido nítrico de tionitrílo de trifenilfosfonio
JP5230755B2 (ja) * 2008-02-22 2013-07-10 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼ阻害剤としてのヘテロ環化合物および組成物
USRE47300E1 (en) 2008-03-14 2019-03-19 Cancure Limited Mitochondrially delivered anti-cancer compounds
CA2760138C (en) * 2009-04-27 2014-11-04 Balaraman Kalyanaraman Neuroprotective compounds and their use
US20110021362A1 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1636572A (zh) * 1998-08-31 2005-07-13 普罗神经细胞有限公司 治疗线粒体性疾病的组合物和方法
CN1454902A (zh) * 2002-04-30 2003-11-12 国际试药株式会社 线粒体肌酸激酶抗体
CN101848918A (zh) * 2007-09-07 2010-09-29 吉奇亚公司 线粒体组合物及其用途

Also Published As

Publication number Publication date
WO2013043580A2 (en) 2013-03-28
HK1200459A1 (en) 2015-08-07
JP2017160254A (ja) 2017-09-14
WO2013043580A3 (en) 2013-06-27
AU2012312654B2 (en) 2017-04-13
US20150005258A1 (en) 2015-01-01
JP2014527969A (ja) 2014-10-23
CA2849073A1 (en) 2013-03-28
AU2012312654A1 (en) 2014-04-03
EP2758411A2 (en) 2014-07-30
US9434753B2 (en) 2016-09-06
CN103889993A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
CN103889993B (zh) 修饰的肌酸化合物
US11339188B2 (en) Compounds for the treatment of cancer
CN114008058B (zh) 用于治疗癌症的cdk抑制剂的前药
CN102471248B (zh) 用于递送1,3-丙二磺酸的方法、化合物和组合物
CN102317257B (zh) 制备不对称双(缩氨基硫脲)的方法
WO2024055112A1 (en) Bifunctional compounds and pharmaceutical uses thereof
CN101848918A (zh) 线粒体组合物及其用途
CN111417620A (zh) 肌酸前药、其组合物以及使用方法
US20180000846A1 (en) Compositions and Methods for Treating Conditions That Affect Epidermis
CA2634217A1 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170531

Termination date: 20190918

CF01 Termination of patent right due to non-payment of annual fee